Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Bluejay Diagnostics Inc (BJDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/18/2025: BJDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -68.59% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.00M USD | Price to earnings Ratio - | 1Y Target Price 256 |
Price to earnings Ratio - | 1Y Target Price 256 | ||
Volume (30-day avg) 49516 | Beta 0.38 | 52 Weeks Range 3.03 - 316.80 | Updated Date 04/2/2025 |
52 Weeks Range 3.03 - 316.80 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -804 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -60.78% | Return on Equity (TTM) -138.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3512758 | Price to Sales(TTM) 54.99 |
Enterprise Value -3512758 | Price to Sales(TTM) 54.99 | ||
Enterprise Value to Revenue 5.67 | Enterprise Value to EBITDA -0.1 | Shares Outstanding 552854 | Shares Floating 141033 |
Shares Outstanding 552854 | Shares Floating 141033 | ||
Percent Insiders 0.69 | Percent Institutions 6.7 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Bluejay Diagnostics Inc
Company Overview
History and Background
Bluejay Diagnostics, Inc. is a point-of-care diagnostics company focused on developing and commercializing cost-effective, rapid, and accurate diagnostic products for acute and chronic disease management. The company was founded in 2016.
Core Business Areas
- Point-of-Care Diagnostics: Develops and commercializes diagnostic products for near-patient testing, allowing for faster results and treatment decisions.
Leadership and Structure
Details on current leadership and organizational structure are not readily available, which includes listing executive names and titles.
Top Products and Market Share
Key Offerings
- SymphChecku2122: A point-of-care triage test used to detect early-stage sepsis in suspected infected patients. Specific market share data for SymphCheck is not publicly available. Competitors include companies offering similar sepsis diagnostic tests like Roche and bioMu00e9rieux.
Market Dynamics
Industry Overview
The point-of-care diagnostics market is experiencing growth due to increasing demand for rapid and convenient testing, technological advancements, and the rising prevalence of infectious diseases. Focus is shifting towards decentralized diagnostics.
Positioning
Bluejay Diagnostics is positioned as a provider of rapid, point-of-care diagnostic solutions, primarily focused on sepsis detection. A competitive advantage would be related to test accuracy, speed, and ease of use.
Total Addressable Market (TAM)
The global sepsis diagnostics market is estimated to be worth billions of USD. Bluejay Diagnosticsu2019 potential is tied to their SymphCheck adoption, testing throughput, and ability to secure market penetration.
Upturn SWOT Analysis
Strengths
- Point-of-care diagnostic focus
- SymphChecku2122 triage test
- Potential for rapid results
Weaknesses
- Limited commercial presence
- Dependence on single product
- Requires regulatory approvals
- High risk of failure
Opportunities
- Expansion into new diagnostic areas
- Strategic partnerships
- Increased adoption of point-of-care testing
- Increased incidence of sepsis
Threats
- Competition from established players
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
- COVID-19
Competitors and Market Share
Key Competitors
- ROCH.SW
- BMY.PA
Competitive Landscape
Bluejay Diagnostics faces intense competition from larger, established players in the diagnostics market. Success depends on product differentiation, effective marketing, and strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends depend on financial performance over several years. Data needed to fill out.
Future Projections: Future growth depends on product adoption, market penetration, and expansion into new areas. Financial reports and estimates are needed.
Recent Initiatives: Recent initiatives information is not readily available without detailed company announcements or news releases.
Summary
Bluejay Diagnostics is a small company with a focus on point-of-care diagnostics, primarily centered around its SymphCheck test for sepsis detection. It has growth potential in a growing market. It faces significant challenges due to intense competition, the need for regulatory approvals, and commercialization hurdles. The company is at high risk due to its small market capitalization and dependance on SymphCheck.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company website
- Market research reports
- Financial news sources
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise. Financial data requires further analysis based on company reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bluejay Diagnostics Inc
Exchange NASDAQ | Headquaters Acton, MA, United States | ||
IPO Launch date 2021-11-10 | Principal Financial, Accounting & Executive Officer, President, CEO and Director Mr. Indranil Dey | ||
Sector Healthcare | Industry Medical Devices | Full time employees 10 | Website https://bluejaydx.com |
Full time employees 10 | Website https://bluejaydx.com | ||
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.